No Data
No Data
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
Smart Money Is Betting Big In VKTX Options
Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics (NASDAQ:VKTX), and it's something market players shouldn't ignore. Our tracking of public options records at
Top Gap Ups and Downs on Wednesday: TSM, NVO, ASML and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Industry shock! Roche's new drug 'scared' the weight loss sector, causing Eli Lilly and co (LLY.US) and Novo Nordisk A/S (NVO.US) to fall.
After Roche (RHHBY.US) announced positive results from its clinical trial of oral weight-loss drugs, the share prices of Eli Lilly and Co (LLY.US) and Novo Nordisk A/S (NVO.US) fell on Wednesday.
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
No Data